Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study - Concepedia

Concepedia

Publication | Open Access

Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study

DOI Full Paper Access

74

Citations

32

References

2023

Year

Hao Fu, Jinxiong Huang, Tianzhi Zhao, Hongjian Wang, Yuhang Chen, Weizhi Xu, Yizhen Pang, Wei Guo, Long Sun, Hua Wu,

Clinical Cancer Research

Abstract

FAP-targeted radioligand therapy with 177Lu-LNC1004 at 3.33 GBq/cycle was well tolerated in patients with advanced mRAIR-TC, with high radiation dose delivery to the tumor lesions, encouraging therapeutic efficacy, and acceptable side effects.

References

	Year	Citations

Page 1